Majluf-Cruz A, Moreno-Hernández M, Alvarado-Moreno LA, Isordia-Salas I, Guardado-Mendoza R, Majluf-Cruz K, Coria-Ramírez E, Hernández-Juárez J

Idioma: Ingles.
Referencias bibliográficas: 47
Paginas: 323-330
Archivo PDF: 158.63 Kb.

RESUMEN

Introducción. La hiperhomocisteinemia es un factor de riesgo trombótico. La homocisteína se evalúa en ayuno y luego de una carga oral de metionina (COM). Objetivo. Establecer la seguridad de la prueba de COM en términos del estado clínico general y las pruebas generales de laboratorio. Material y métodos. Se estudiaron adultos de ambos sexos, sanos y no fumadores, y pacientes con diversas condiciones trombóticas. Antes y después de recibir la COM se obtuvieron muestras de sangre para realizar las pruebas de laboratorio. También se evaluaron los efectos adversos agudos y sub-agudos y la morbilidad y mortalidad asociadas a los 30 días. De 353 individuos, tres fueron eliminados ya que no toleraron la COM. Se estudiaron 175 individuos sanos y 175 pacientes sin diferencias significativas en términos de edad. Luego de la COM se encontraron algunas alteraciones clínicas leves y moderadas en 78 individuos (22.1%): náusea (n = 69; 88.5%), mareo (n = 13; 16.7%) y aumento o disminución de la presión arterial (n = 8; 10.2%). La náusea siempre desapareció luego del desayuno. La prevalencia de las complicaciones fue similar en los pacientes y en los controles. Ningún paciente requirió hospitalización y la mortalidad en los 30 días del periodo de estudio fue cero. Conclusión. La COM no induce efectos indeseables significativos sobre el estado clínico o las pruebas de laboratorio en pacientes y en voluntarios sanos. La COM se asocia con algunos efectos clínicos leves a moderados, pero no afecta ninguna prueba de laboratorio significativamente. Por lo tanto, la COM es una prueba diagnóstica segura en pacientes con eventos trombóticos previos que son portadores de factores de riesgo asociados como diabetes mellitus o dislipidemia, así como en controles sanos.

REFERENCIAS (EN ESTE ARTÍCULO)

1. Finch JM, Joseph J. Homocysteine, cardiovascular inflammation, and myocardial remodeling. Cardiovasc Hematol Disord Drug Targets 2010; 10: 241-5.

2. Lippi G, Plebani M. Hyperhomocysteinemia in health and disease: where we are now, and where do we go from here? Clin Chem Lab Med 2012 [Epub ahead of print].

3. Maron BA, Loscalzo J. Homocysteine. Clin Lab Med 2006; 26: 591-609.

4. Zepeda-Gómez S, Montano-Loza A, Zapata-Colindres JC, Vargas- Vorackova F, Majluf-Cruz A, Uscanga L. Oral challenge with a methionine load in patients with inflammatory bowel disease: a better test to identify hyperhomocysteinemia. Inflamm Bowel Dis 2008; 14: 383-8.

5. Carson NAJ, Cusworth DC, Dent CE, Field CMB, Neill DW, Westall RG. Homocystinuria: A new inborn error of metabolism associated with mental deficiency. Arch Dis Child 1963; 38: 425-36.

6. Fowler B, Sardharwalla IB, Robins AJ. The detection of heterozygotes for homocystinuria bye oral loading with L-methionine. Biochem J 1971; 122: 23-4.

7. Lievers KJA, Kluijtmans LAJ, Heil SG, Borres GHL, Verhoef P, van Oppenraay-Emmerzaal D, et al. A 31 bp VNTR in the cystathionine b-synthase (CBS) gene is associated with reduced CBS activity and elevated post-load homocysteine levels. Eur J Human Gen 2001; 9: 583-9.

8. de Jong SC, Stehouwer CDA, van den Berg M, Kostense PJ, Alders D, Jakobs C, et al. Determinants of fasting and post-methionine homocysteine levels in families predisposed to hyperhomocysteinemia and premature vascular disease. Arterioscler Thromb Vasc Biol 1999; 19; 1316-24.

9. Atkinson W, Elmslie J, Lever M, Chambers ST, George PM. Dietary and supplementary betaine: acute effects on plasma betaine and homocysteine concentrations under standard and postmethionine load conditions in healthy male subjects. Am J Clin Nutr 2008; 87: 577-85.

10. Gerdes VEA, Kremer Hovinga HA, Ten Cate H, MacGillavry MR, Leijte A, Reirsma PH, et al. Homocysteine and markers of coagulation and endothelial cell activation. J Thromb Haemost 2004; 2: 445-51.

11. Maron BA, Loscalzo J. The treatment of hyperhomocysteinemia. Annu Rev Med 2009; 60: 39-54.

12. Ganji V, Kafai MR. Demographic, health, lifestyle, and blood vitamin determinants of serum total homocysteine concentrations in the third National Health and Nutrition Examination Survey, 1988-1994. Am J Clin Nutr 2003; 77: 826-33.

13. Sassi S, Cosme B, Palareti G, Legnani C, Grossi G, Musolesi S, et al. Influence of age, sex and vitamin status on fasting and post-methionine load plasma homocysteine levels. Haematologica 2002; 87: 957-64.

14. Refsum H, Smith AD, Ueland PM, Nexo E, Clarke R, McPartlin J, Johnston C, et al. Facts and recommendations about total homocysteine determinations: an expert opinion. Clin Chem 2004; 50: 3-32.

15. de Jonge R, Griffioen PH, van Zelst B, Brouns RM, Visser W, Lindemans J. Evaluation of a shorter methionine loading test. Clin Chem Lab Med 2004; 42: 1027-31.

16. Hart SR, Mangoni AA, Swift CG, Jackson SH. Effect of methionine loading on pulse wave analysis in elderly volunteers. Postgrad Med J 2006; 82: 524-7.

17. Krupková-Meixnerová L, Veselá K, Vitová A, Janosíková B, Andel M, Kozich V. Methionine-loading test: evaluation of adverse effects and safety in an epidemiological study. Clin Nutr 2002; 21: 151-6.

18. Hart SR, Mangoni AA, Swift CG, Jackson SH. Lack of significant effects of methionine loading on endothelial function in elderly volunteers. Heart Lung Circ 2006; 15: 358-61.

19. Silberger J, Dudman N. Methionine loading. In: Carmel R, Jacobsen DW (eds.). Homocysteine in health and disease. Cambridge University Press: The Press Syndicate of the University of Cambridge; 2001, p. 212-9.

20. Pasternak RC, Grundy SM, Levy D, Thompson PD. 27th Bethesda Conference: matching the intensity of risk factor management with the hazard for coronary disease events. Task Force 3. Spectrum of risk factors for coronary heart disease. J Am Coll Cardiol 1996; 27: 978-90.

21. Harjai KJ. Potential new cardiovascular risk factors: left ventricular hypertrophy, homocysteine, lipoprotein(a), triglycerides, oxidative stress, and fibrinogen. Ann Intern Med 1999; 131: 376-86.

22. Alemán G, Tovar A, Torres N. Metabolismo de la homocisteína y riesgo de enfermedades cardiovasculares: importancia del estado nutricio en ácido fólico, vitaminas B6 y B12. Rev Inv Clin 2001; 53: 141-51.

23. Boers GH, Smals AG, Trijbels FJ, Fowler B, Bakkeren JAJM, Schoonderwaldt HC, et al. Heterozygosity for homocystinuria in premature peripheral and cerebral occlusive arterial disease. N Engl J Med 1985; 313: 709-15.

24. Clarke R, Daly L, Robinson K, Naughten E, Cahalane S, Fowler B, et al. Hyperhomocysteinemia: an independent risk factor for vascular disease. N Engl J Med 1991; 324: 1149-55.

25. Malinow MR, Bostom AG, Krauss RM. Homocyst(e)ine, diet, and cardiovascular diseases: a statement for healthcare profes sionals from the Nutrition Committee, American Heart Association. Circulation 1999; 99: 178-82.

26. Shoob HD, Sargent RG, Thompson SJ, Best RG, Drane JW, Tocharoen A. Dietary methionine is involved in the etiology of neural tube defect-affected pregnancies in humans. J Nutr 2001; 131: 2653-8.

27. Floyd JC Jr., Fajans SS, Conn JW, Knopf RF, Rull J. Stimulation of insulin secretion by amino acids. J Clin Invest 1966; 45: 1487-502.

28. Perry TL, Hardwick DF, Dixon GH, Dolman CL, Hansen S. Hypermethioninemia: a metabolic disorder associated with cirrhosis, islet cell hyperplasia, and renal tubular degeneration. Pediatrics 1965;36:236-250.

29. Cohen SM, Nichols A, Wyatt R, Pollin W. The administration of methionine to chronic schizophrenic patients: a review of ten studies. Biol Psychiatry 1974; 8: 209-25.

30. Korokin MV, Pokrovskiy MV, Novikov OO, Gudyrev OS, Gureev VV, Denisyuk TA, et al. A model of hyperhomocysteineinduced endothelial dysfunction in rats. Bull Exp Biol Med 2011; 152: 213-5.

31. Munjal C, Tyagi N, Lominadze D, Tyagi SC. Matrix metalloproteinase- 9 in homocysteine-induced intestinal microvascular endothelial paracellular and transcellular permeability. J Cell Biochem 2012; 113: 1159-69.

32. Chao CL, Kuo TL, Lee YT. Effects of methionine-induced hyperhomocysteinemia on endothelium-dependent vasodilation and oxidative status in healthy adults. Circulation 2008; 101: 485-90.

33. Cheng Z, Jiang X, Kruger WD, Praticò D, Gupta S, Mallilankaraman K, et al. Hyperhomocysteinemia impairs endotheliumderived hyperpolarizing factor-mediated vasorelaxation in transgenic cystathionine beta synthase-deficient mice. Blood 2011; 118: 1998-2006.

34. Doshi S, McDowell I, Goodfellow J, Stabler S, Boger R, Allen R, et al. Relationship between S-adenosylmethionine, S-adenosylhomocysteine, asymmetric dimethylarginine, and endothelial function in healthy human subjects during experimental hyperand hypohomocysteinemia. Metabolism 2005; 54: 351-60.

35. Chambers JC, McGregor A, Jean-Marie J, Obeid OA, Kooner JS. Demonstration of rapid onset vascular endothelial dysfunction after hyperhomocysteinemia: an effect reversible with vitamin C therapy. Circulation 1999; 99: 1156-60.

36. Usui M, Matsuoka H, Miyazaki H, Ueda S, Okuda S, Imaizumi T. Endothelial dysfunction by acute hyperhomocyst(e)inaemia: restoration by folic acid. Clin Sci (Lond) 1999; 96: 235-9.

37. He L, Zeng H, Li F, Feng J, Liu S, Liu J, et al. Homocysteine impairs coronary artery endothelial function by inhibiting tetrahydrobiopterin in patients with hyperhomocysteinemia. Am J Physiol Endocrinol Metab 2010; 299: E1061-E1065.

38. Hladovec J, Sommerová Z, Písarikova A. Homocysteinemia and endothelial damage after methionine load. Thromb Res 1997; 88: 361-4.

39. Herrmann W, Stanger O, Knapp JP, Semmelrock HJ, Lemmerer M, Rigler B. Post-methionine-load hyperhomocysteinemia and increased lipoprotein(a) are associated with renal metabolic dysfunction: a hypothesis. Metabolism 2002; 51: 1235-40.

40. Chao CL, Lee YT. Impairment of cerebrovascular reactivity by methionine-induced hyperhomocysteinemia and amelioration by quinapril treatment. Stroke 2000; 31: 2907-11.

41. O’Dochartaigh C, Ong H, Lovell S, Donnelly R, Hanratty C, Riley M, et al. Changes in pulmonary vascular function after acute methionine loading in normal men. Clin Sci (Lond) 2004; 106: 413-9.

42. Domagala TB, Libura M, Szczeklik A. Hyperhomocysteinemia following oral methionine load is associated with increased lipid peroxidation. Thromb Res 1997; 87: 411-6.

43. Tousoulis D, Bouras G, Antoniades C, Marinou K, Miliou A, Papageorgiou N, et al. The activation of endothelin-1 pathway during methionine-induced homocysteinemia mediates endothelial dysfunction in hypertensive individuals. J Hypertens 2010; 28: 925-30.

44. Ventura P, Panini R, Verlato C, Scarpetta G, Salvioli G. Peroxidation indices and total antioxidant capacity in plasma during hyperhomocysteinemia induced by methionine oral loading. Metabolism 2000; 49: 225-8.

45. Selhub J, Jacques PF, Wilson PW, Rush D, Rosenberg IH. Vitamin status and intake as primary determinants of homocysteinemia in an elderly population. JAMA 1993; 270: 2693-8.

46. Labinjoh C, Newby DE, Wilkinson IB, Megson IL, MacCallum H, Melville V, et al. Effects of acute methionine loading and vitamin C on endogenous fibrinolysis, endothelium-dependent vasomotion and platelet aggregation. Clin Sci (Lond) 2001; 100: 127-35.

47. De Caterina R. Endothelial dysfunctions: common denominators in vascular disease. Curr Opin Clin Nutr Metab Care 2000; 3: 453-67.